国产药物洗脱支架治疗冠状动脉病变的近期疗效

以Cypher支架为代表的药物洗脱支架（Drugs—Eluting Stent，DES）对单支初发病变较金属裸支架在降低支架内再狭窄方面有明确疗效。最近献报道了Cypher支架在复杂病变中取得的满意结果。本研究探讨FIRE BIRD（火鸟金属支架，上海微创公司）支架的近期疗效。     

国产与进口西罗莫司药物洗脱支架治疗冠心病临床疗效对比

目的评估国产西罗莫司药物洗脱冠状动脉(冠脉)支架在冠心病患者中应用的安全性及1年临床随访结果,并与同期应用进口药物洗脱支架(Cypher和Taxus)比较。方法与结果2003年5月至2004年6月,共计673例经冠脉造影证实的冠心病患者接受药物洗脱支架治疗,其中接受国产西罗莫司药物洗脱支架(Firebird,上海微创公司)224例,进口西罗莫司药物洗脱支架(Cypher,美国强生公司)246例,进口紫杉醇药物洗脱支架(Taxus,美国波士顿公司)203例。各组基础临床情况及造影特征均相似,尽管Firebird组患者平均每例置入支架数目较多且支架总长度较长,但其住院总费用仍显著低于其他两组。术后1年临床随访严重心脏不良事件(包括心源性死亡、非致命性心肌梗死和靶血管再次血运重建)发生率在Firebird组为9·0%、Cypher组为8·4%、Taxus组为11·2%,相互比较差异无统计学意义。造影证实Firebird组2例(0·9%)、Cypher组2例(0·9%)和Taxus组3例(1·6%)发生支架内血栓形成。结论国产西罗莫司药物洗脱冠脉支架治疗冠心病安全,其1年临床疗效与进口西罗莫司及紫杉醇药物洗脱冠脉支架相似。     

国产与进口雷帕霉素药物洗脱支架治疗冠心病的疗效比较

药物洗脱支架是目前治疗冠心病的主要方式之一，它可以使支架内再狭窄的发生率下降至10％以内。目前进口雷帕霉素药物洗脱支架（美国Cordis公司，支架名称Cypher）已广泛应用于冠心病患，而国产药物洗脱支架（上海微创医疗器械公司生产，支架名称Firebird）在临床应用的安全性和有效性有待研究。     

药物洗脱支架治疗冠脉病变的近期疗效

目的　观察药物洗脱支架治疗冠脉病变的近期疗效。方法　采用经皮冠脉方法 ,对 2 9例冠心病病人进行 3 1例次介入治疗。术后随访采用临床观察及冠脉造影评价其近期疗效。结果　 2 9例冠心病中不稳定性心绞痛 1 7例 ,急性心肌梗死 9例 ,冠脉支架内再狭窄 3例 ,共植入药物洗脱支架 3 3只 ,其中CypherTM支架 2 6只 ,TAXUS支架 7只。全部病例随访 3～ 1 4个月 ,除一例术后死亡外 ,无一例发现胸痛及支架内再狭窄的临床表现。 3例随访中作冠脉造影 ,显示DES内无再狭窄征象。结论　药物洗脱支架治疗冠脉病变的近期疗效肯定 ,且无不良事件增加 ,对具有高度再狭窄可能的复杂病变 ,亦可获益。     

国产西罗莫司药物洗脱支架治疗冠心病331例的疗效及安全性

目的探讨国产西罗莫司药物洗脱支架治疗冠心病的安全性与有效性。方法对331例冠心病患者采用经股动脉途径冠状动脉造影及常规方法行国产药物洗脱支架置入术,记录住院期间主要不良心脏事件(MACE)发生情况,术后1年随访,6~9个月行冠状动脉造影复查。结果331例冠心病患者共置入支架597只,均成功置入病变处;1例心源性休克行急诊经皮冠状动脉介入治疗(PC I)支架置入后3 h死于泵衰竭,1例发生血管破裂转外科行急诊冠状动脉旁路移植术,3例术后出现非Q波型心肌梗死,住院期间MACE发生率为1.5%。301例患者随访12.3±3.2个月,2例死亡,2例支架内血栓形成,1例非致死性心肌梗死,16例再次心绞痛发作,5例再次靶病变血运重建术,总的MACE发生率为4.3%;110例患者6~9个月行冠状动脉造影复查,6例支架内再狭窄,再狭窄率5.5%。结论国产西罗莫司药物洗脱支架治疗冠心病患者安全、有效,有较好的近、中期疗效和较高的效益/价格比,尤其适用于经济欠发达地区,可使更多冠心病患者受益;但其远期效果有待进一步研究。     

国产药物洗脱支架在急诊冠脉介入治疗后近期疗效观察

急性心肌梗死治疗的关键是梗死相关动脉（IRA）的快速开通,直接经皮冠状动脉介入（PCI）治疗ST段抬高心肌梗死（STEMI）已取得显著疗效,但是国产药物洗脱支架在急诊PCI治疗中的应用报道尚少。     

国产西罗莫司洗脱支架治疗冠心病的近远期疗效

目的评价国产西罗莫司洗脱支架（Firebird）在冠心病患者中应用的近、远期疗效。方法2003年11月至2005年1月共410例冠心病患者（460处病变）置入Firebird支架501个。所有患者术前、术后均给予足量抗血小板药物,通过门诊或电话随访,部分患者进行了冠状动脉造影复查来评估Firebird支架在国人冠心病治疗中的临床疗效。结果手术成功率99．5％,术中有1例支架内血栓形成;术后住院期间有1例猝死,主要不良心脏事件（包括死亡、非致死性心肌梗死和靶病变血管重建术）发生率为0．2％（1／410）;376例患者完成随访,随访率91．7％,平均随访时间（12．8±3．2）个月,死亡3例,非致死性心肌梗死4例,11例进行了再次靶病变重建术,主要不良心脏事件发生率为4．3％（16／376）,支架内血栓发生率1．1％（4／376）。102例（122处病变）进行冠状动脉造影复查,支架内再狭窄率占所有随访患者的2．9％（12／418）,占所有造影复查的9．8％（12／122）。结论Firebird支架在国人冠心病介入治疗中的应用是安全和有效的,但尚需大规模的随机对照试验来评价。     

国产雷帕霉素涂层支架治疗冠心病的疗效观察

目的评价冠心病患者接受国产雷帕霉素涂层支架治疗的近期疗效及安全性。方法选择接受雷帕霉素涂层支架植入术患者60例,观察患者术后的即刻疗效和1-12个月临床疗效。结果60例患者共处理118处冠脉病变,共植入121枚支架,其中B2型以上复杂病变40例,占66.7%（98处）,长支架（〉20 mm）23例（38.3%）,小血管支架（2.50-2.75 mm）16例（26.7%）,手术即刻成功率100%,术中无严重并发症发生。随访1-12个月,无严重心脏不良事件发生。结论国产雷帕霉素涂层支架治疗冠脉病变近期安全有效。     

国产药物洗脱支架治疗冠心病合并糖尿病的临床分析

目的 评价国产药物洗脱支架(PARTNER)治疗冠心病合并糖尿病患者的安全性和可行性.方法 75 例冠心病合并2型糖尿病患者置入PARTNER支架,术后对患者进行随访,观察有无胸痛复发,心电图改变及重要心血管不良事件的发生.结果 75例患者共置入PARTNER 支架129枚,手术即刻成功率100%,对患者随诊9个月～12个月,不良事件发生率8%,其中急性心肌梗死2例(1例死亡),支架内再狭窄4例.结论 PARTNER置入即刻成功率高,能有效预防术后.冠心病合并糖尿病患者应用国产药物洗脱支架置入即刻成功率高,近期疗效满意.     

雷帕霉素药物支架治疗冠心病的远期疗效

目的 评价雷帕霉素药物洗脱支架（Firebird^TM）在冠心病患者介入治疗中的疗效及其安全性。方法 药物支架组患者接受Firebird^TM支架治疗的老年冠心病患者52例（72枚）,普通支架组为选择同期接受普通冠状动脉支架治疗的冠心病患者43例（53枚）,比较两组的临床特征、支架置入情况及临床事件发生率。结果 药物支架组中的糖尿病患者占46．2％,明显高于普通支架组（34．9％,P〈0．05）;干预的病变血管呈弥漫性病变,药物支架组占40．9％,高于普通支架组（28.3％,P〈0．05）;病变血管平均参考内径,药物支架组为（2．63±0．23）mm,普通支架组为（3．12±0．17）mm,差异有统计学意义（P〈0．05）;置入支架内径和长度,药物支架组分别为（2．75±0．22）mm和（23．1±4．0）mm,普通支架组分别为（3．05±0．19）mm和（15．6±3．3）m,差异有统计学意义（P〈0．05）。随访12～18个月,心绞痛复发率,药物支架组3．8％,普通支架组16．3％;靶病变血管再次血运重建率,药物支架组0,普通支架组9．3％,P〈0．05）。结论 Firebird^TM支架治疗冠心病安全有效,对冠状动脉弥漫性病变、小血管病变的也有较好的疗效。其近期及远期临床效果均优于普通支架。     

Short-term clinical outcome of drug-eluting coronary stent

Objective To evaluate short-term outcome of coronary drug-eluting stent (DES) in patients with coronary artery disease (CAD) by comparing with standard bare stents.     

国产药物洗脱支架在冠心病复杂病变中的应用研究

目的 探讨国产药物洗脱支架在冠状动脉粥样硬化性心脏病(冠心病)复杂病变患者中应用的安全性及临床疗效.方法 将215例确诊为冠心病的患者分为3组:单枚支架植入组(n=75)、两支架植入组(n=72)和多枚(≥3枚)支架植入组(n=68),术后长期随访,观察术后12个月随访终点时支架内再狭窄发生率及主要心血管事件(包括死亡...     

药物洗脱支架与裸支架介入治疗冠心病的对比研究

目的比较冠心病患者应用药物洗脱支架与应用裸支架的安全性和有效性。方法回顾我院2006—2011年行冠脉支架置入术患者的随访结果,比较应用药物洗脱支架与裸支架的再狭窄率。结果应用药物洗脱支架患者的再狭窄率为8％,应用裸支架患者的再狭窄率为25％,两者相比差异有统计学意义。结论药物洗脱支架较裸支架具有更低的支架内再狭窄发生率。     

Relationship between hyperhomocysteine and long-term outcome of coronary artery disease patients after drug-eluting stent implantation

<正>Objective To explore the relationship between hyperhomocysteinemia(H-Hcy)and long-term outcome of coronary artery disease(CAD)patients after drug-eluting stent(DES)implantation in a single centre.Methods A total of 1 408 consecutive patients implanted with DES in our department between March 2011 and January 2013     

Complete versus incomplete revascularization for treatment of multivessel coronary artery disease in the drug-eluting stent era

Limited data exist regarding the impact of complete revascularization (CR) versus incomplete revascularization (IR) on the long-term outcomes of patients with multivessel coronary artery disease (MVD) who underwent percutaneous coronary intervention with drug-eluting stents. We compared major adverse cardiac events [MACE: death, myocardial infarction (MI), or any revascularization] in 873 patients and in 255 pairs generated by propensity-score matching. CR was performed in 427 patients (48.9%) and IR in 446 (51.1%). While the amount of myocardium at risk by the APPROACH score was similar between two groups (56.0?±?14.4 vs. 56.7?±?16.1, p?=?0.49), the SYNTAX score was lower in the CR group than in the IR group (20.7?±?9.4 vs. 23.3?±?10.7, p?<?0.01). MACE occurred in 203 patients (23.3%) during a median follow-up of 35?months. CR was associated with a lower incidence of MACE (HR 0.64; 95% CI 0.46–0.88; p?<?0.01) and revascularization (HR 0.61; 95% CI 0.42–0.90; p?=?0.01), but not of death (HR 0.87; 95% CI 0.48–1.57; p?=?0.64) and MI (HR 0.62; 95% CI 0.23–1.67; p?=?0.35). The incidence of periprocedural MI and stent thrombosis was similar in two groups (4.7% in the CR group vs. 3.6% in the IR group, p?=?0.42; 1.6 vs. 1.3%, p?=?0.72, respectively). After propensity-score matching, patients with CR had fewer MACE and revascularization than those with IR. In patients with MVD, CR strategy using drug-eluting stents could reduce repeat revascularization with similar death, MI, and stent thrombosis risk compared with IR strategy.     

Impact of metabolic syndrome on clinical outcomes after drug-eluting stent implantation in patients with coronary artery disease

Metabolic syndrome (MetS) is regarded as a risk factor for coronary artery disease (CAD). However, the influence of MetS on morbidity and mortality after drug-eluting stent (DES) implantation in Chinese patients with CAD remains unknown. We evaluated the impact of MetS on the clinical outcome of 1224 patients following DES implantation. After a mean follow-up of 35.4 months, patients with MetS had a significantly higher incidence of all-cause death and major adverse cardiovascular events (MACE) compared with patients without MetS (P < .001). Analyses of individual MetS components showed that dysglycemia at the time of DES implantation predicted increased all-cause mortality, while the presence of hypertension and dysglycemia predicted increased incidence of MACE.     

置入国产雷帕霉素药物洗脱支架冠心病患者双联抗血小板治疗效果的研究

目的:对置入国产雷帕霉素支架(Firebird)的冠心病患者,12个月双联抗血小板(DAPT)后继续延长DAPT时间能否获益进行分析。方法:回顾性分析2007年1月至2009年12月,于北京安贞医院心内科置入Firebird支架的患者,按照DAPT的时间,分为12个月停用DAPT组和12个月DAPT组,通过门诊或电话随访,评价术后患者死亡、心肌梗死、脑卒中联合终点发生率,靶血管再次血运重建发生率。结果:共入选患者1 073例,随访平均(29.4±6.2)个月,按照排除标准筛选后共955例患者纳入分析,12个月停用DAPT患者410例,12个月DAPT组患者545例。12个月停用DAPT和12个月DAPT组死亡/心肌梗死/脑卒中发生率分别为5.2和1.6,P=0.016,多因素校正后,12个月停用DAPT组仍较12个月DAPT组显著增加死亡/心肌梗死/脑卒中风险(HR=3.56,95%CI:1.18~10.8,P=0.025)。结论:对于置入Firebird的患者,与12个月时停用DAPT仅使用阿司匹林比较,12个月后继续使用DAPT显著降低不良事件风险。     

Comparison of long-term outcome of off-pump coronary artery bypass grafting versus drug-eluting stents in triple-vessel coronary artery disease

After the introduction of drug-eluting stents (DESs), percutaneous coronary intervention with DESs has challenged coronary artery bypass grafting as the gold standard for the treatment of 3-vessel coronary artery disease. The purpose of this study was to compare the long-term clinical results between percutaneous coronary intervention with DESs and off-pump coronary artery bypass grafting (OPCAB) in 3-vessel coronary artery disease. Two hundred ninety propensity-score matched patients with 3-vessel coronary artery disease treated by DESs or OPCAB were included. Mean follow-up duration was 58.8 ± 11.5 months (2 to 73) and follow-up rate was 97.9%. Five-year survival rates were 94.8 ± 2.1% in the DES group and 96.5 ± 1.5% in the OPCAB group (p = 0.658). Five-year rates of freedom from major adverse cardiac and cerebrovascular event were 71.6 ± 4.1% in the DES group and 89.6 ± 2.5% in the OPCAB group (p < 0.001). Freedom from nonfatal myocardial infarction and target vessel revascularization rates were the determining factors between the 2 groups (p = 0.018 and p < 0.001, respectively). The OPCAB group showed better clinical outcomes compared to the DES group in 3-vessel coronary artery disease after 5-year follow-up. Freedom from major adverse cardiac and cerebrovascular event rate was significantly higher in the OPCAB group mainly because of the lower incidence of target vessel revascularization and nonfatal myocardial infarction. Longer follow-up with randomization will clarify our present conclusions.